Flash Sell! Let’s Protect Our Gains In This Machine Vision Play

By Ray BlancoPosted April 6, 2018

Despite a decline in shares, we're up 103% on this one! Time to take the gain while we're up...

You Must Be A Subscriber To View This Content.

If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!

Technology Profits Confidential

With new technologies in mobile computing, biotechnology and 3-D printing, it’s nearly impossible to keep up with the throngs of new innovation and still be able to forecast which companies are set to profit. Technology Profits Confidential is your one-stop shop for the companies of tomorrow’s technology… and how you can profit from them.

Ray Blanco

Ray Blanco is the editor of Technology Profits Confidential as well as Breakthrough Technology Alert, Ray Blanco’s FDA Trader, Penny Pot Profits and Technology Profits Daily. Ray has been with Seven Figure Publishing for nine years. In 2018, his closed positions in Technology Profits Confidential averaged over 100% gains.

View More By Ray Blanco

Tech Companies Showcase Innovations at CES

By Ray BlancoPosted January 11, 2013

January is a busy time for technology and biotechnology companies. During the early weeks of the year, tech companies show off their latest innovations at the Consumer Electronics Show in Las Vegas. Biotech companies, on the other hand, engage investors at what is likely the year's largest biotech investor event -- the JP Morgan Healthcare Conference. I'm reviewing those presentations in the hunt for the next great biotechnology investment.

Regulatory Moves, Trial Results and More!

By Ray BlancoPosted November 30, 2012

All the attention is on fiscal cliffs, but our biotechnology specialists are climbing mountains. Thanksgiving's over and they are heading into the year's final inning strong. I have updates for you on several of them.

Ebola Reaches the U.S.

By Ray BlancoPosted October 3, 2014

It appears Ebola has reared its ugly head on this side of the Atlantic. With the burgeoning number of infections overseas, it was only a matter of time. A Liberian citizen infected with the virus by the name of Thomas Eric Duncan boarded a flight bound out of Liberia's capital and, by a circuitous route through several countries, ended up in Texas. As many as 100 Americans are suspected of possible exposure and are being watched. His family here in the States is under quarantine and observation. His home country is considering charging him with a crime for doing this, but considering the deadly nature of the disease and the severe strain on a Liberian health care system that is turning sick people away from hospitals because it can't handle any more cases, his decision could be considered rational, if saving his your own life is the ultimate consideration. In a U.S. hospital, with the best supporting care and possible access to an experimental drug, Duncan at least has a fighting chance to live.

InterDigital Ends Strategic Review Process

By Ray BlancoPosted January 27, 2012

InterDigital (NASDAQ: IDCC) announced that it has concluded its attempt at putting the company up for sale. The company initiated the process last summer after large wireless players showed a ravenous appetite for smaller companies with valuable intellectual property portfolios. The market didn't like this news and the company's share price swooned on Tuesday.

Agora’s Investor Symposium a Beacon in Dark Times

By Ray BlancoPosted July 29, 2011

The valuable information presented at this year's symposium, titled "Fight or Flight," has been both scary and hopeful. Presentations by many of our gifted thinkers, such as John Mauldin, have put an exclamation mark on the dire fiscal situation the country is in.

Next-Generation Antibody Companies Ink New Partnership Deals — Plus, 2 Sells

By Ray BlancoPosted January 10, 2014

In biotechnology, one way to get a feel for a new therapeutic platform's potential for success is relationships. A really promising platform will generally attract the attention of other players who want a piece of the action. Big Pharma has essentially “pharmed out” a lot of the drug discovery and development it used to do with emerging biotech companies. But if one of the new upstarts is truly promising in the opinion of the experts working at these companies, a couple of things can happen. One is a partnership, either on an existing drug under development at the junior company or for a collaboration to use that company's technology to develop a drug that doesn't exist yet. The second thing, of course, is an outright buyout of the smaller firm.

Login